Delving into the Latest Updates on ASP-1948 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

ASP 1948, PTZ-329, anti-neuropilin-1 antibody ASP1948

Target

NRP-1

Action

inhibitors

Mechanism

NRP-1 inhibitors(Neuropilin-1 inhibitors)

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Advanced Malignant Solid NeoplasmLocally Advanced Malignant Solid Neoplasm

Originator Organization

Astellas Pharma, Inc.

Active Organization-

Inactive Organization

Astellas Pharma Global Development, Inc.

Astellas Pharma, Inc.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab and determine the recommended Phase 2 dose (RP2D) of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab. This study will also evaluate the antitumor effect of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab.

Start Date02 Jul 2018

Sponsor / Collaborator

Astellas Pharma Global Development, Inc.

[+1]

100 Clinical Results associated with ASP-1948

Login to view more data

100 Translational Medicine associated with ASP-1948

Login to view more data

100 Patents (Medical) associated with ASP-1948

Login to view more data

100 Deals associated with ASP-1948

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	Japan	Astellas Pharma Global Development, Inc.	02 Jul 2018
Locally Advanced Malignant Solid Neoplasm	Phase 1	United States	Astellas Pharma Global Development, Inc.	02 Jul 2018
Locally Advanced Malignant Solid Neoplasm	Phase 1	Canada	Astellas Pharma Global Development, Inc.	02 Jul 2018
Locally Advanced Malignant Solid Neoplasm	Phase 1	Italy	Astellas Pharma Global Development, Inc.	02 Jul 2018
Locally Advanced Malignant Solid Neoplasm	Phase 1	Portugal	Astellas Pharma Global Development, Inc.	02 Jul 2018
Locally Advanced Malignant Solid Neoplasm	Phase 1	Spain	Astellas Pharma Global Development, Inc.	02 Jul 2018
Locally Advanced Malignant Solid Neoplasm	Phase 1	Taiwan Province	Astellas Pharma Global Development, Inc.	02 Jul 2018
Locally Advanced Malignant Solid Neoplasm	Phase 1	United Kingdom	Astellas Pharma Global Development, Inc.	02 Jul 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data